Author Archives: Chandra Ganegoda

BriaCell’s Bria-IMT(TM) Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy ...

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

  [IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor ...

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study

IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS ...

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard ...

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 ...

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study ...

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ ...

BriaCell Bria-OTS(TM) Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase ...

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in ...